All In Biotech

Drug Trial Radar · NCT07736391

A Study of SYH2069 Injection in Healthy Participants

A Randomized, Double-blind, Placebo-controlled, Dose-escalation Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of SYH2069 Injection in Healthy Participants

Last checked: Nov 19, 2026Latest source record: Jul 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 104 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

104

Actual

Start

Jan 10, 2026

Primary completion

Jul 30, 2026

Study completion Nov 30, 2026

Sponsor

Sponsor type
Industry
First posted
Jul 30, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

To evaluate the safety and tolerability of single and multiple doses of SYH2069 Injection in healthy participants.

Conditions

  • Overweight or Obesity
  • Diabetes

Interventions

  • SYH2069 InjectionDrug

    A subcutaneous injection in the abdomen of the corresponding dose of SYH2069 Injection according to the assigned dose cohort.

  • PlaceboDrug

    A subcutaneous injection in the abdomen of the corresponding dose of Placebo according to the assigned dose cohort.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with treatment-related adverse events as accessed by CTCAE v6.0Time frame: SAD: Screening period up to day 29 MAD: Screening period up to day 50

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The Affiliated Hospital of Nanjing University Medical School

    Nanjing, Jiangsu, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.